# GLP-1 Eligibility in Australia: A Survey Estimate of 7.8 Million Adults | Buy This GLP

Australia’s 2022 health survey suggests 39.7% of adults met approved GLP-1 weight-management criteria. See how researchers estimated cardiovascular eligibility.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/australia-glp1-eligible-population
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# GLP-1 Eligibility in Australia: A Survey Estimate of 7.8 Million Adults

An analysis of Australia’s 2022 National Health Survey estimated that 39.7% of adults met the approved weight-management criteria and up to 338,900 potentially met the cardiovascular criteria.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

Australian eligibility estimates from 2022 survey data · weight management — 7.8 million (39.7% of adults) · cardiovascular — up to 338.9 thousand · 2.9 million met the weight criteria without a comorbidity. · Estimates based on approved indications and survey data.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   Researchers applied Australian regulatory criteria to weighted results from the 2022 National Health Survey.
-   An estimated 39.7% of adults, about 7.8 million, met criteria for chronic weight management.
-   Up to 338,900 of those adults potentially met the cardiovascular criteria. That upper estimate includes people with possible established cardiovascular disease.

## How the study estimated weight-management eligibility

Researchers applied the Therapeutic Goods Administration’s approved indications to data from 13,039 Australian adults. The chronic weight-management indication uses an initial BMI of at least 30, or a BMI of at least 27 but below 30 with at least one weight-related condition. The weighted estimate was 39.7% (95% confidence interval, 38.4% to 41.0%), or 7.8 million adults (7.6 million to 8.1 million). An estimated 2.9 million met the criteria without a weight-related comorbidity.[\[1\]](https://buythisglp.com/research/australia-glp1-eligible-population#ref-1)[\[2\]](https://buythisglp.com/research/australia-glp1-eligible-population#ref-2)

Australian subsidy decisions use separate criteria. The guide to [U.S. Wegovy coverage](https://buythisglp.com/research/wegovy-label-change-coverage) illustrates how an approved indication can be relevant to a coverage decision under a different system. For a U.S. example, the [Form Health review](https://buythisglp.com/reviews/form-health) describes the clinic’s separate enrollment criteria. The Australian survey estimated how many adults matched its regulator’s indications. It did not measure who received a prescription or a subsidy.[\[1\]](https://buythisglp.com/research/australia-glp1-eligible-population#ref-1)

## Why the cardiovascular estimate is an upper bound

Australia’s Wegovy indication for cardiovascular risk reduction requires established cardiovascular disease, a BMI of at least 27, and no established type 1 or type 2 diabetes. The researchers estimated that 285,700 adults met their definition of confirmed established disease. Including 53,200 adults who met their broader definition of possible established disease gave an upper estimate of 338,900 (95% confidence interval, 271,300 to 406,500).[\[1\]](https://buythisglp.com/research/australia-glp1-eligible-population#ref-1)[\[2\]](https://buythisglp.com/research/australia-glp1-eligible-population#ref-2)

The 2022 survey used directly measured height and weight when available. About 40.8% of respondents lacked measured BMI. For those respondents, the Australian Bureau of Statistics estimated height and weight using reported values and other variables. The survey could not reliably identify some contraindications or verify every cardiovascular diagnosis.[\[1\]](https://buythisglp.com/research/australia-glp1-eligible-population#ref-1)

## What changed after the study

Australia registered Wegovy tablets on November 3, 2026, for chronic weight management and cardiovascular risk reduction in adults. The TGA’s November assessment lists the same adult eligibility thresholds for the injection and the tablet. The registration does not change the 2022 survey population used for the estimates.[\[2\]](https://buythisglp.com/research/australia-glp1-eligible-population#ref-2)

## Frequently asked

How many Australian adults met the GLP-1 weight-management criteria?

A weighted analysis of the 2022 Australian National Health Survey estimated 39.7% of adults, about 7.8 million, met the approved weight-management criteria.

How many met the cardiovascular criteria?

Researchers estimated up to 338,900 adults potentially met the criteria when including possible cases of established cardiovascular disease. About 285,700 met their definition of confirmed disease.

Did the study measure who received subsidised treatment?

It estimated how many adults met approved indications using survey data. Subsidy, prescribing, and treatment uptake are separate questions.

## Sources

1.  \[1\] Castrillon J, et al. (2026). Estimating Eligibility for GLP-1 Receptor Agonists for Chronic Weight Management and Cardiovascular Disease in Australia: Cross-Sectional Analysis of National Health Survey Data The Medical Journal of Australia. [PMID 42604458](https://onlinelibrary.wiley.com/doi/full/10.5694/mja2.70253)
2.  \[2\] Therapeutic Goods Administration (2026). Australian Public Assessment Report for Wegovy Australian Government. [Source](https://www.tga.gov.au/resources/auspar/wegovy)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
